Hims stock price reacts strongly to crucial FDA review [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The immediate catalyst was the FDA's decision to hold a July 23-24 meeting of its Pharmacy Compounding Advisory Committee to review whether several peptides should be considered for broader compounding access. The agency's agenda includes BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, and Epitalon. Reuters said the FDA's move helped send Hims shares higher as investors started pricing in a potential long-term opening for the category. Reuters reported on April 16 that Hims shares rose more than 7% after the FDA development, while other market coverage showed the rally building over several sessions as investors connected the regulatory review to Hims' existing peptide ambitions. The setup gave traders a fresh growth narrative at a moment when the company's weight-loss business is already being reworked around a broader mix of approved treatments. Hims had already been building toward peptides In February 2025, Hims announced that it had acquired a California-based peptide
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) [Yahoo! Finance]Yahoo! Finance
- How Dave Ricks keeps Lilly looking beyond its hit weight loss drugs [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Hims & Hers jumps 7% after expanding partnership with Eli Lilly [Yahoo! Finance]Yahoo! Finance
- Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website